研究者詳細 - 満間　綾子

A Prospective Cohort Study Exploring the Effect of Lenvatinib Planned Drug Holidays in Treatment of Differentiated Thyroid Cancer

Tahara, M; Takami, H; Ito, Y; Okamoto, T; Sugitani, I; Sugino, K; Takahashi, S; Takeyama, H; Tsutsui, H; Hara, H; Mitsuma, A; Yamashita, H; Ohashi, Y; Imai, T

THYROID 34 巻 ( 5 ) 頁： 566 - 574 2024年5月

記述言語：英語出版者・発行元：Thyroid

Background: Although lenvatinib is the preferred treatment for unresectable radioactive iodine-refractory differentiated thyroid cancer (RR-DTC), this agent exerts considerable toxicities, which can lead to frequent dose interruptions and modifications. The adoption of planned drug holidays has been recently suggested as one means of minimizing or avoiding these severe adverse events. Our retrospective study demonstrated that planned drug holidays appear to be a promising strategy for continuing of lenvatinib. However, the benefits of planned drug holidays in a prospective study have yet to be clarified. Here, we investigated the impact of planned drug holidays on clinical outcomes in patients treated with lenvatinib in the COLLECT study. Methods: In COLLECT, a prospective observational study, patients with RR-DTC were treated with lenvatinib in a real-world clinical setting. Lenvatinib was administered orally at a dose of 24 mg daily. Dose modification for toxicities was permitted. Furthermore, planned drug holidays were allowed to avoid severe or intolerable toxicities. The present post hoc analysis focused on evaluating the impact of planned drug holidays on clinical outcomes, including overall survival (OS), time to treatment failure (TTF), time to failure strategy (TFS), and progression-free survival (PFS), in patients in the COLLECT study who were treated with lenvatinib. Results: In total, 262 patients were included. Of the 253 patients evaluable for efficacy, 73 undertook a planned drug holiday at the discretion of the attending physician. OS, TTF, TFS, and PFS were significantly longer in patients who used a planned drug holiday than in those who did not. The planned drug holiday group demonstrated notable clinical outcomes, with a 1-year OS of 95.8% and a 1-year PFS of 94.5%. Moreover, planned drug holidays demonstrated a clinically meaningful advantage in clinical outcomes. The planned drug holiday group had a significantly longer duration of administration at a dose of ≥10 mg. Conclusions: Planned drug holidays for lenvatinib were associated with significantly improved clinical outcomes compared to daily oral administration. Further investigation of the optimal treatment schedule for lenvatinib is warranted. Clinical Trial Registration: UMIN000022243.

DOI： 10.1089/thy.2023.0553

A phase I study of LCL161, a novel oral pan-inhibitor of apoptosis protein (IAP) antagonist, in Japanese patients with advanced solid tumors

特集化学療法誘発性末梢神経障害(CIPN)　～しびれに悩む患者に,なにができるか～ Ⅰ.CIPNとは CIPNの機序

満間綾子

がん看護 28 巻 ( 6 ) 頁： 533 - 536 2023年7月

Analysis of the COLLECT Study - Efficacy and safety of lenvatinib in differentiated thyroid cancer

Iwasaki Hiroyuki, Takami Hiroshi, Yasuhiro Ito, Takahiro Okamoto, Iwao Sugitani, Kiminori Sugino, Shunji Takahashi, Hiroshi Takeyama, Hidemitsu Tutui, Hisato Hara, Ayako Mitsuma, Hiroyuki Yamashita, Yasuo Ohashi, Takeru Shiroiwa, Tuneo Imai, Makoto Tahara

ANNALS OF ONCOLOGY 33 巻頁： S466 - S467 2022年7月

Morita Sachi, Minami Hironobu, Mitsuma Ayako, Toyoda Masanori, Kiyota Naomi, Ando Yuichi

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 2022年1月

記述言語：日本語出版者・発行元：Asia-Pacific Journal of Clinical Oncology

Introduction: LCL161 is a novel oral pan-inhibitor of apoptosis protein (IAP) antagonist. LCL161 enhances paclitaxel activity in cell lines and xenograft models. A phase I study of LCL161 combined with paclitaxel for the treatment of Japanese patients with advanced solid tumors was conducted. Methods: Each patient received oral LCL161 in a single weekly dose on days 1, 8, and 15 of a 21-day treatment cycle. In the second cycle, patients received a combination treatment with weekly paclitaxel (80 mg/m2) whenever possible. A Bayesian logistic regression model by escalation with the overdose control principle was used. Results: Nine patients were treated with LCL161 at a dose of 600 mg (five patients) or 1200 mg (four patients). Seven patients were treated with LCL161 plus paclitaxel, and two patients received only LCL161 monotherapy. Because this study was terminated early due to a change in the LCL161 development strategy, the maximum tolerated dose (MTD) was not determined. One patient treated with LCL161 monotherapy at a dose of 1200 mg experienced dose limitind toxicity (grade 3 maculopapular rash). Another patient died on day 86 of bacterial pneumonia, which was suspected to be related to the study treatment. The most common serious adverse events were infections and infestations (n = 3). Conclusion: The present study suggests that the risk of infection may increase when LCL161 is combined with paclitaxel, but other conclusions about the MTD, pharmacokinetic profile, and preliminary activity of the combination of LCL161 plus paclitaxel were not drawn.

DOI： 10.1111/ajco.13744

Chemotherapy for Older Patients with Cancer

Mitsuma A., Ando Y.

Gan to kagaku ryoho. Cancer & chemotherapy 49 巻 ( 1 ) 頁： 13 - 18 2022年1月

出版者・発行元：Gan to kagaku ryoho. Cancer & chemotherapy

Older patients with cancer are different physically, psycho-spirituality, and socio-economically, and when considering the indications for chemotherapy and other drug therapies for cancer, it is important to comprehensively assess their condition and risk using geriatric assessment(GA). Multidisciplinary team-based approach is essential to address impaired domains that are found by GA. The G8 screening is useful tool for screening the GA candidates. In recent years, there have been increasing opportunities that older patients with cancer who receive immunotherapy with immune checkpoint inhibitors. There is no consensus on the treatment and management of immune-related adverse events(irAEs)specific to older patients, and therefore it is important to adhere to an evidence-based approach.

Collision Tumors of Gastric Adenocarcinoma and Mucosa-associated Lymphoid Tissue Lymphoma

Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancer

Takano Yuko, Furune Satoshi, Miyai Yuki, Morita Sachi, Inoue Megumi, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi

INTERNATIONAL CANCER CONFERENCE JOURNAL 11 巻 ( 1 ) 頁： 67 - 70 2022年1月

Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment

Furune Satoshi, Kondo Chiaki, Takano Yuko, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi

INTERNATIONAL CANCER CONFERENCE JOURNAL 11 巻 ( 1 ) 頁： 46 - 48 2022年1月

[Chemotherapy for Older Patients with Cancer].

Mitsuma A, Ando Y

Gan to kagaku ryoho. Cancer & chemotherapy 49 巻 ( 1 ) 頁： 13 - 18 2022年1月

Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment (Oct, 10.1007/s13691-021-00515-w, 2021)

Furune Satoshi, Kondo Chiaki, Takano Yuko, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi

INTERNATIONAL CANCER CONFERENCE JOURNAL 11 巻 ( 1 ) 頁： 49 - 49 2022年1月

A case of recurrent gastric cancer with drug-induced immune thrombocytopenia caused by trastuzumab

Takano Yuko, Furune Satoshi, Morita Sachi, Inoue Megumi, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Osamu Maeda, Ando Yuichi

ANNALS OF ONCOLOGY 32 巻頁： S354 - S354 2021年7月

Planned drug holiday in a cohort study exploring the effect of lenvatinib on differentiated thyroid cancer.

Tahara Makoto, Takami Hiroshi, Ito Yasuhiro, Okamoto Takahiro, Sugitani Iwao, Sugino Kiminori, Takahashi Shunji, Takeyama Hiroshi, Tsutsui Hidemitsu, Hara Hisato, Mitsuma Ayako, Yamashita Hiroyuki, Ohashi Yasuo, Imai Tsuneo

JOURNAL OF CLINICAL ONCOLOGY 39 巻 ( 15 ) 2021年5月

Kobayashi Kenichi, Furukawa Kazuhiro, Ishikawa Eri, Mitsuma Ayako, Funasaka Kohei, Kakushima Naomi, Furune Satoshi, Ito Nobuhito, Wada Hirotaka, Hirose Takashi, Muroi Koichi, Suzuki Tomohiko, Suzuki Takahiro, Hida Emiko, Hirai Keiko, Shibata Hiroyuki, Koya Toshinari, Nakamura Masanao, Kawashima Hiroki, Miyahara Ryoji, Fujishiro Mitsuhiro

INTERNAL MEDICINE 60 巻 ( 15 ) 頁： 2419 - 2424 2021年

記述言語：日本語出版者・発行元：一般社団法人日本内科学会

<p>A 65-year-old woman with a history of treatment for splenic marginal zone B-cell lymphoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma underwent esophagogastroduodenoscopy. A reddish elevated lesion was found in the fundus of the stomach. On image-enhanced endoscopy, several findings, such as glandular structures of varying sizes suggesting well-differentiated adenocarcinoma, pruned blood vessels, and dilated blood vessels in deeper mucosa suggesting MALT lymphoma, were observed. The final pathological diagnosis after surgical resection was collision tumors of well-differentiated adenocarcinoma and MALT lymphoma. The features of both tumors could be observed simultaneously with image-enhanced endoscopy. </p>

DOI： 10.2169/internalmedicine.6124-20